Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tear proteomics, efficacy and safety of 0.1% cyclosporine vs 0.05% cyclosporine and 3% diquafosol in moderate to severe dry eye
KCT0007857Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of cyclosporine and diquafosol in dry eye syndrome (DED), sponsored by Santen Pharmaceutical. Started Jun 2019; status: completed.
02
Drugs
cyclosporinediquafosol
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on KCT0007857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007857.